NCT05943886View on ClinicalTrials.gov

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

February 17, 2023

Study Completion Date

February 17, 2023

Conditions
Healthy SubjectsObesityT2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

HEC88473 injection

HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

DRUG

Placebo

Placebo will be administered by subcutaneous injection in the abdomen.

Trial Locations (1)

130000

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Dongguan HEC Biopharmaceutical R&D Co., Ltd.

INDUSTRY

NCT05943886 - A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects | Biotech Hunter | Biotech Hunter